Publicaciones en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (60)

2023

  1. Apremilast treatment of plaque psoriasis (PsO) after systemic therapy in Spanish clinical practice: Data from the APPROPRIATE study

    JEADV Clinical Practice, Vol. 2, Núm. 3, pp. 488-501

  2. Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population

    Australasian Journal of Dermatology, Vol. 64, Núm. 4, pp. e317-e326

  3. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 12, pp. 2517-2525

  4. Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)

    Dermatology and Therapy, Vol. 13, Núm. 1, pp. 329-345

  5. Erythrodermic Psoriasis Has Become Less Frequent: Results From the Biobadaderm Registry

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 4, pp. T366-T369

  6. Generalized Pustular Psoriasis: A Review on Clinical Characteristics, Diagnosis, and Treatment

    Dermatology and Therapy, Vol. 13, Núm. 3, pp. 673-688

  7. Generalized pustular psoriasis: practical recommendations for Spanish primary care and emergency physicians

    Postgraduate Medicine, Vol. 135, Núm. 8, pp. 766-774

  8. High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting

    International Journal of Dermatology

  9. Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice

    Journal of the European Academy of Dermatology and Venereology

  10. Selection of Quality Indicators for the Certification of Psoriasis Units: The CUDERMA Project Delphi Consensus Study

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 10, pp. 865-883

  11. Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 10, pp. 2004-2015